Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy.

Conclusions: The combined treatment of DPP4i and ARBs is superior to ARBs alone, as evidenced by the greater proteinuria reduction and lower eGFR decline. In addition, the renoprotection of DPP4i combined with ARBs was independent of glycemic control. PMID: 30425192 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30425192?dopt=Abstract

Source: Chinese Medical Journal - November 15, 2018 Category: General Medicine Authors: Qiu DD, Liu J, Shi JS, An Y, Ge YC, Zhou ML, Jiang S Tags: Chin Med J (Engl) Source Type: research